These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27671498)

  • 1. Identification and optimization of a new series of anti-tubercular quinazolinones.
    Couturier C; Lair C; Pellet A; Upton A; Kaneko T; Perron C; Cogo E; Menegotto J; Bauer A; Scheiper B; Lagrange S; Bacqué E
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5290-5299. PubMed ID: 27671498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F
    Jian Y; Forbes HE; Hulpia F; Risseeuw MDP; Caljon G; Munier-Lehmann H; Boshoff HIM; Van Calenbergh S
    J Med Chem; 2021 Jan; 64(1):440-457. PubMed ID: 33347317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1H-Benzo[d]imidazoles and 3,4-dihydroquinazolin-4-ones: Design, synthesis and antitubercular activity.
    Macchi FS; Pissinate K; Villela AD; Abbadi BL; Rodrigues-Junior V; Nabinger DD; Altenhofen S; Sperotto N; da Silva Dadda A; Subtil FT; de Freitas TF; Erhart Rauber AP; Borsoi AF; Bonan CD; Bizarro CV; Basso LA; Santos DS; Machado P
    Eur J Med Chem; 2018 Jul; 155():153-164. PubMed ID: 29885576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, crystal structure and biological evaluation of substituted quinazolinone benzoates as novel antituberculosis agents targeting acetohydroxyacid synthase.
    Lu W; Baig IA; Sun HJ; Cui CJ; Guo R; Jung IP; Wang D; Dong M; Yoon MY; Wang JG
    Eur J Med Chem; 2015 Apr; 94():298-305. PubMed ID: 25771108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of phaitanthrin congeners as anti-mycobacterial agents.
    Kamal A; Reddy BV; Sridevi B; Ravikumar A; Venkateswarlu A; Sravanthi G; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3867-72. PubMed ID: 26253635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
    Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis.
    Taneja NK; Tyagi JS
    J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione derivatives as novel antibacterial compounds against
    Koseki Y; Kanetaka H; Tsunosaki J; Munier-Lehmann H; Aoki S
    Int J Mycobacteriol; 2017; 6(1):61-69. PubMed ID: 28317807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and molecular docking study of novel triazole-quinazolinone hybrids as antimalarial and antitubercular agents.
    Mhetre UV; Haval NB; Bondle GM; Rathod SS; Choudhari PB; Kumari J; Sriram D; Haval KP
    Bioorg Med Chem Lett; 2024 Aug; 108():129800. PubMed ID: 38763480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
    Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
    Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
    Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.
    Hwang JM; Oh T; Kaneko T; Upton AM; Franzblau SG; Ma Z; Cho SN; Kim P
    J Nat Prod; 2013 Mar; 76(3):354-67. PubMed ID: 23360475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.
    Palencia A; Li X; Bu W; Choi W; Ding CZ; Easom EE; Feng L; Hernandez V; Houston P; Liu L; Meewan M; Mohan M; Rock FL; Sexton H; Zhang S; Zhou Y; Wan B; Wang Y; Franzblau SG; Woolhiser L; Gruppo V; Lenaerts AJ; O'Malley T; Parish T; Cooper CB; Waters MG; Ma Z; Ioerger TR; Sacchettini JC; Rullas J; Angulo-Barturen I; Pérez-Herrán E; Mendoza A; Barros D; Cusack S; Plattner JJ; Alley MR
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6271-80. PubMed ID: 27503647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
    Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
    Altaf M; Miller CH; Bellows DS; O'Toole R
    Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, docking analysis, identification, and synthesis of novel 3-(((substituted phenyl) amino)methyl)-2-methylquinazolin-4(3H)-one compounds to fight tuberculosis.
    Panneerselvam T; Sivakumar A; Arumugam S; Joshi SD
    Drug Discov Ther; 2016; 10(4):188-94. PubMed ID: 27594295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors.
    Fang C; Lee KK; Nietupski R; Bates RH; Fernandez-Menendez R; Lopez-Roman EM; Guijarro-Lopez L; Yin Y; Peng Z; Gomez JE; Fisher S; Barros-Aguirre D; Hubbard BK; Serrano-Wu MH; Hung DT
    Bioorg Med Chem Lett; 2018 Dec; 28(22):3529-3533. PubMed ID: 30316633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore.
    Salunke SB; Azad AK; Kapuriya NP; Balada-Llasat JM; Pancholi P; Schlesinger LS; Chen CS
    Bioorg Med Chem; 2015 May; 23(9):1935-43. PubMed ID: 25818768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.
    Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sheikh MG; Rane R; Basu R; Verma P; Sundaram A; Mukherjee K; de Sousa SM
    J Biomol Screen; 2015 Feb; 20(2):265-74. PubMed ID: 25300873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.